First in Human Study for PF-06667272
Status and phase
Completed
Phase 1
Conditions
Healthy
Treatments
Drug: PF-06667272
Other: Placebo
Study type
Interventional
Funder types
Industry
Identifiers
Details and patient eligibility
About
The current study is the first clinical trial proposed with PF-06667272. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single ascending doses of PF-06667272 under fed and fasted conditions, in healthy adult subjects.
Enrollment
16 patients
Sex
All
Ages
18 to 55 years old
Volunteers
Accepts Healthy Volunteers
Inclusion criteria
- Healthy males and female of non-childbearing potential;
- Body Mass Index 17.5-30.5 kg/m2;
- Body weight >50 kg;
Exclusion criteria
- Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
Trial design
Primary purpose
Basic Science
Allocation
Randomized
Interventional model
Sequential Assignment
Masking
Double Blind
16 participants in 16 patient groups, including a placebo group
Cohort 1_Period 1_Active
Experimental group
Description:
Single ascending dose of PF-06667272
Treatment:
Drug: PF-06667272
Cohort 1_Period 1_Placebo
Placebo Comparator group
Description:
Single dose of placebo
Treatment:
Other: Placebo
Cohort 1_Period 2_Active
Experimental group
Description:
Single ascending dose of PF-06667272
Treatment:
Drug: PF-06667272
Cohort 1_Period 2_Placebo
Placebo Comparator group
Description:
Single dose of placebo
Treatment:
Other: Placebo
Cohort 1_Period 3_Active
Experimental group
Description:
Single ascending dose of PF-06667272
Treatment:
Drug: PF-06667272
Cohort 1_Period 3_Placebo
Placebo Comparator group
Description:
Single dose of placebo
Treatment:
Other: Placebo
Cohrot 1_Period 4_Active
Experimental group
Description:
Single ascending dose of PF-06667272
Treatment:
Drug: PF-06667272
Cohort 1_Period 4_Placebo
Placebo Comparator group
Description:
Single dose of placebo
Treatment:
Other: Placebo
Cohort 2_Period 1_Active
Experimental group
Description:
Single ascending dose of PF-06667272
Treatment:
Drug: PF-06667272
Cohort 2_Period 1_Placebo
Placebo Comparator group
Description:
Single dose of placebo
Treatment:
Other: Placebo
Cohort 2_Period 2_Active
Experimental group
Description:
Single ascending dose of PF-06667272
Treatment:
Drug: PF-06667272
Cohort 2_Period 2_Placebo
Placebo Comparator group
Description:
Single dose of placebo
Treatment:
Other: Placebo
Cohort 2_Period 3_Active
Experimental group
Description:
Single ascending dose of PF-06667272
Treatment:
Drug: PF-06667272
Cohort 2_Period 3_Placebo
Placebo Comparator group
Description:
Single dose of placebo
Treatment:
Other: Placebo
Cohort 2_Period 4_Active
Experimental group
Description:
Single ascending dose of PF-06667272
Treatment:
Drug: PF-06667272
Cohort 2_Period 4_Placebo
Placebo Comparator group
Description:
Single dose of placebo
Treatment:
Other: Placebo
Trial contacts and locations
1
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems